BioNano Genomics, Inc. WT EXP 082123 (BNGOW)

BioNano Genomics, Inc. WT EXP 082123 (BNGOW) Healthcare & Pipeline Overview

BioNano Genomics, Inc. offers genome analysis solutions, primarily through its Saphyr system, which enables structural variation analysis via optical genome mapping. Targeting the medical diagnostics and research sector, the company provides integrated hardware, software, and services, competing in a landscape of genetic analysis technologies.

What Is the Investment Thesis for BNGOW?

BioNano Genomics operates in the growing field of genome analysis, with its Saphyr system offering a unique approach to structural variation analysis. The company's gross margin of 46.5% indicates potential for profitability as adoption increases. Growth catalysts include expanding applications of OGM in clinical diagnostics and research. However, the company's negative profit margin of -134.4% highlights the need for improved cost management and revenue scaling. Investors should monitor the company's ability to increase Saphyr system placements, expand its service offerings, and achieve profitability in a competitive market. The company's beta of 2.06 suggests higher volatility compared to the overall market.

Based on FMP financials and quantitative analysis

BNGOW Key Highlights

• Gross Margin of 46.5% indicates potential for profitability as the company scales its operations and increases adoption of its Saphyr system.
• Beta of 2.06 suggests higher volatility compared to the overall market, reflecting the growth stage and speculative nature of the company.
• Focus on structural variation analysis through optical genome mapping (OGM) provides a differentiated approach in the genome analysis market.
• Offers a comprehensive suite of products and services, including the Saphyr system, NxClinical software, and various genetic testing services.
• Serves the medical diagnostics and research industry, addressing the needs of researchers and clinicians in understanding genetic variation and function.

Who Are BNGOW's Competitors?

BNGOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BNGOW's Key Strengths?

• Proprietary Saphyr system for structural variation analysis.
• Integrated solution with hardware, software, and consumables.
• Established customer base in research and clinical settings.
• Expertise in optical genome mapping and genomic data analysis.

What Are BNGOW's Weaknesses?

• Negative profit margin (-134.4%) indicates financial challenges.
• Limited market share compared to larger competitors.
• Reliance on a single product line (Saphyr system).
• Requires significant capital investment for research and development.

What Could Drive BNGOW Stock Higher?

• Expansion of clinical applications for the Saphyr system, potentially leading to increased adoption in diagnostic settings.
• Continued research and development efforts to enhance the capabilities of the Saphyr system and expand its applications.
• Strategic partnerships and collaborations with pharmaceutical companies and research institutions to accelerate the adoption of BioNano Genomics' technology.

What Are the Key Risks for BNGOW?

• Negative return on equity (-71.4%) — the business is not currently generating profit on shareholder capital.
• Competition from companies offering alternative genomic analysis technologies, such as next-generation sequencing (NGS).
• Regulatory hurdles and reimbursement challenges for genetic testing, which could limit adoption of the Saphyr system in clinical settings.
• The company's negative profit margin (-134.4%) indicates financial challenges and the need for improved cost management.
• Technological advancements that could render the Saphyr system obsolete or less competitive.

What Are the Growth Opportunities for BNGOW?

• Expansion of Saphyr System Applications: BioNano Genomics can expand the applications of its Saphyr system in areas such as cancer research, drug discovery, and personalized medicine. The market for genomic analysis in cancer research is projected to reach billions of dollars, offering a significant opportunity for BioNano Genomics to increase its market share by demonstrating the utility of OGM in identifying structural variations associated with cancer development and progression. Timeline: Ongoing.
• Increased Adoption in Clinical Diagnostics: The company can drive adoption of its OGM technology in clinical diagnostics by obtaining regulatory approvals and demonstrating clinical utility. The market for genetic testing is growing, driven by increasing awareness of genetic disorders and the availability of new diagnostic tools. BioNano Genomics can capitalize on this trend by expanding its menu of clinical assays and partnering with hospitals and diagnostic laboratories. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and other healthcare providers can accelerate the adoption of BioNano Genomics' technology and expand its market reach. Collaborations can provide access to new markets, funding, and expertise, enabling the company to develop new applications for its technology and strengthen its competitive position. Timeline: Ongoing.
• Development of New Products and Services: BioNano Genomics can invest in the development of new products and services that complement its existing offerings and address unmet needs in the market. This could include developing new sample preparation methods, software tools, and data analysis pipelines. By expanding its product portfolio, the company can attract new customers and increase its revenue streams. Timeline: Ongoing.
• Geographic Expansion: BioNano Genomics can expand its geographic presence by entering new markets in Asia, Europe, and other regions. The global market for genome analysis is growing, driven by increasing investments in healthcare and research. By establishing a presence in key markets, the company can access new customers and increase its global market share. Timeline: Ongoing.

What Opportunities Does BNGOW Have?

• Expansion of Saphyr system applications in cancer research and drug discovery.
• Increased adoption in clinical diagnostics through regulatory approvals.
• Strategic partnerships with pharmaceutical companies and research institutions.
• Development of new products and services to complement existing offerings.

What Threats Does BNGOW Face?

• Competition from companies offering next-generation sequencing (NGS) and microarray technologies.
• Regulatory hurdles and reimbursement challenges for genetic testing.
• Technological advancements that could render the Saphyr system obsolete.
• Economic downturn that could reduce funding for research and healthcare.

What Are BNGOW's Competitive Advantages?

• Proprietary Technology: The Saphyr system and optical genome mapping technology provide a differentiated approach to structural variation analysis.
• Integrated Solution: The company offers a complete solution, including hardware, software, and consumables, creating a barrier to entry for competitors.
• Established Customer Base: BioNano Genomics has built a customer base of research institutions, hospitals, and pharmaceutical companies.
• Expertise and Know-How: The company has developed expertise in optical genome mapping and genomic data analysis.

What Does BNGOW Do?

Founded in 2003 and headquartered in San Diego, California, BioNano Genomics, Inc. has evolved into a provider of genome analysis solutions, focusing on the understanding of genetic variation and function. The company's flagship product is the Saphyr system, a sample-to-result solution for structural variation analysis using optical genome mapping (OGM). Saphyr integrates a single-molecule imager, specialized consumables like the Saphyr Chip, and Bionano Prep Kits for DNA extraction and labeling. These components enable researchers and clinicians to visualize and analyze the structural organization of the genome. Beyond the Saphyr system, BioNano Genomics offers compute servers and the NxClinical software, which allows for the analysis and interpretation of genomic variants from microarray and next-generation sequencing data. The company also provides testing and laboratory services, including FirstStepDx PLUS for chromosomal microarray analysis, Fragile X syndrome (FXS) testing, NextStepDx PLUS for exome sequencing, EpiPanelDx PLUS for seizure-related genetic testing, and PGx testing for pharmacogenomics. These services cater to individuals with autism spectrum disorder, developmental delay, intellectual disability, and other genetic conditions. BioNano Genomics aims to advance the understanding and application of genomics in both research and clinical settings.

What Products and Services Does BNGOW Offer?

• Provides the Saphyr system for structural variation analysis using optical genome mapping.
• Offers Saphyr Chips, consumables containing nanochannel arrays for DNA linearization.
• Develops Bionano Prep Kits and DNA labeling kits for extracting and labeling ultra-high molecular weight DNA.
• Provides Saphyr and Bionano compute servers for data processing and analysis.
• Offers NxClinical software for analysis and interpretation of genomic variants from microarray and next-generation sequencing data.
• Provides testing and laboratory services, including chromosomal microarray analysis and exome sequencing.

How Does BNGOW Make Money?

• Sells the Saphyr system, a hardware platform for optical genome mapping.
• Generates recurring revenue through the sale of consumables, such as Saphyr Chips and reagent kits.
• Offers software licenses for NxClinical, a platform for genomic data analysis and interpretation.
• Provides testing and laboratory services, including genetic testing for various disorders.

What Industry Does BNGOW Operate In?

BioNano Genomics operates within the medical diagnostics and research industry, which is experiencing growth driven by advancements in genomic technologies and increasing demand for personalized medicine. The market for genome analysis is competitive, with companies offering various solutions for sequencing, microarray analysis, and optical genome mapping. BioNano Genomics differentiates itself with its Saphyr system, which focuses on structural variation analysis. The company competes with firms offering next-generation sequencing (NGS) and microarray-based technologies. The industry is characterized by ongoing innovation, regulatory scrutiny, and the need for cost-effective solutions.

Who Are BNGOW's Key Customers?

• Research institutions conducting genomic research.
• Hospitals and clinical laboratories performing genetic testing.
• Pharmaceutical companies involved in drug discovery and development.
• Academic medical centers studying genetic disorders.

BioNano Genomics, Inc. WT EXP 082123 Financial Trajectory

BioNano Genomics, Inc. WT EXP 082123 (BNGOW) reported $6.7M in revenue for Q1 2026, a decline of 15.9% compared to the prior quarter. The company recorded a net loss of $8.3M, with diluted EPS of $-0.76. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, BNGOW averaged $-1.45 in diluted EPS.

Company Profile

BioNano Genomics, Inc. WT EXP 082123 operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO None. BNGOW has traded publicly since 2018.

ROE -71%Key Financial Metrics

Return on equity for BioNano Genomics, Inc. WT EXP 082123 stands at -71.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.8%, showing how much profit it generates from its asset base. A current ratio of 1.84 indicates the company holds enough short-term assets to cover its near-term obligations.

BNGOW Financials

BNGOW Latest News

No recent news available for BNGOW.

BNGOW Analyst Consensus

BNGOW MoonshotScore

BioNano Genomics, Inc. WT EXP 082123 Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources